Fosbretabulin

Summary

Fosbretabulin (CHEMBL1206232) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including neoplasm and neuroendocrine neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 8
• Chemistry: 396.3 Da · C18H21O8P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1206232
Name	Fosbretabulin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5351387
Molecular formula	C18H21O8P
Molecular weight	396.3
InChIKey	WDOGQTQEKVLZIJ-WAYWQWQTSA-N

SMILES: COC1=C(C=C(C=C1)/C=C\C2=CC(=C(C(=C2)OC)OC)OC)OP(=O)(O)O

IUPAC name: [2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate

Also known as: Combretastatin a-4 phosphate, Combretastatin a4 phosphate, Fosbretabulin, Fosbretabulina, Fosbretabuline, Phosbretabulin, Combretastatin A-4 phosphate, Combretastatin A4 phosphate, Combretastatin A-4 disodium phosphate, Combretastain A4 phosphate, FOSBRETABULIN, Fosbretabulin (disodium)

Parent form; salt/anhydrous children: CHEMBL263994, CHEMBL289351, CHEMBL1972559, CHEMBL2105643

Patent coverage: 643 distinct patent families (2,116 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,801 (85%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	2	MONDO:0005070	EFO:0000616
neuroendocrine neoplasm	2	MONDO:0019496	EFO:1001901
ovarian cancer	1	MONDO:0008170	MONDO:0008170
ovarian neoplasm	1	MONDO:0021068	EFO:0003893

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	4
PHASE1/PHASE2	2
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01701349	PHASE3	WITHDRAWN	Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
NCT00653939	PHASE2	COMPLETED	A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
NCT01023295	PHASE2	COMPLETED	Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)
NCT01423149	PHASE2	COMPLETED	Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
NCT01570790	PHASE1/PHASE2	COMPLETED	Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
NCT02055690	PHASE1/PHASE2	TERMINATED	PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
NCT02279602	PHASE2	COMPLETED	Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
NCT03014297	PHASE1	TERMINATED	Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).